DOCSLIB.ORG

Prior Authorization Protocol ALOXI® (Palonosetron), ANZEMET

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prior Authorization Protocol ALOXI® (Palonosetron), ANZEMET Prior Authorization Protocol ALOXI (palonosetron), ANZEMET (dolasetron), SANCUSO , GRANISOL ™ (granisetron) NATL Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document. I. FDA Approved Indications: Granisetron Anzemet Anzemet Granisetron Sancuso Aloxi injection tablet & injection tablet injection patch Granisol Moderately emetogenic X cancer X Patient is chemotherapy X In adults receiving (MEC)- Also approved and chemotherapy prevention of for delayed X X children 2 regimens up acute nausea & nausea and years and to 5 vomiting vomiting older consecutive associated with days duration initial and repeat courses X Also indicated in pediatric patients aged 1 month to Highly less than 17 years emetogenic for prevention of X cancer acute nausea and Patient is chemotherapy vomiting receiving (HEC)- associated with chemotherapy prevention of initial and repeat X X regimens up acute nausea & courses of to 5 vomiting emetogenic consecutive associated with cancer days duration initial and chemotherapy, repeat courses. including highly emetogenic cancer chemotherapy Prevention of nausea & vomiting X associated with radiation (RINV), Draft Prepared: December 17, 2002 1 Approved by Health Net Pharmacy and Therapeutics Committee: 4.11.06, 5.16.07, 05.21.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 10.17.03, 1.24.05, 12.07.05 RJL, 01.02.06 JP, 02.06.06 RJL, 02.27.06 RJL, 08.18.06 RO, 04.03.07 RO, 9.20.07 RO, 1.04.08 RO, 08.08.08 RO, 08.01.09 R Olegario, 10.26.10 R Olegario, 06.07.11 A Giordano, 7.12.12 R. Gedey, 07.11.13 MJMcClusky,07.07.14 S Mirando, 06.19.15 T You02.10S Ahantab, 12.15.16 M Del Nero Prior Authorization Protocol ALOXI (palonosetron), ANZEMET (dolasetron), SANCUSO , GRANISOL ™ (granisetron) NATL Granisetron Anzemet Anzemet Granisetron Sancuso Aloxi injection tablet & injection tablet injection patch Granisol including total body irradiation and fractionated abdominal radiation X Used for up to X Prevention of 24 hours In adults postoperative following and nausea and surgery. X children 2 vomiting Efficacy beyond years and (PONV). 24 hours has older not been demonstrated X Treatment of In adults postoperative and nausea and X children 2 vomiting years and (PONV) older II. Health Net Approved Indications and Usage Guidelines: Prevention of nausea and vomiting associated with cancer chemotherapy for Anzemet tablet, Granisetron injection and tablet, Granisol and Sancuso patch: • Patient has received, or will receive, highly or moderately emetogenic chemotherapy AND • Failure or clinically significant adverse events to ondansetron or Aloxi Prevention of nausea and vomiting associated with radiation therapy (RINV) for Granisetron tablet and Granisol: • Patient will receive radiation therapy AND • Failure or clinically significant adverse events to ondansetron Prevention of postoperative nausea and vomiting (PONV) for Aloxi, Anzemet injection and Granisetron injection: • Patient is undergoing surgery AND Draft Prepared: December 17, 2002 2 Approved by Health Net Pharmacy and Therapeutics Committee: 4.11.06, 5.16.07, 05.21.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 10.17.03, 1.24.05, 12.07.05 RJL, 01.02.06 JP, 02.06.06 RJL, 02.27.06 RJL, 08.18.06 RO, 04.03.07 RO, 9.20.07 RO, 1.04.08 RO, 08.08.08 RO, 08.01.09 R Olegario, 10.26.10 R Olegario, 06.07.11 A Giordano, 7.12.12 R. Gedey, 07.11.13 MJMcClusky,07.07.14 S Mirando, 06.19.15 T You02.10S Ahantab, 12.15.16 M Del Nero Prior Authorization Protocol ALOXI (palonosetron), ANZEMET (dolasetron), SANCUSO , GRANISOL ™ (granisetron) NATL • Failure or clinically significant adverse events to ondansetron Treatment of PONV for Anzemet injection and Granisetron injection: • Patient underwent surgery AND • 5-HT 3 antagonist was not used for prevention of PONV III. Coverage is Not Authorized For: • Non-FDA approved indications, which are not listed in the Health Net Approved Indications and Usage Guidelines section unless there is sufficient documentation of efficacy and safety in the published literature. • Anzemet injection solution is contraindicated in adult and pediatric patients for the prevention of nausea and vomiting associated with the initial and repeat courses of emetogenic cancer chemotherapy IV. General Information: • The NCCN Antiemesis guidelines Version 1.2012 added Aloxi as the preferred 5HT-3 antagonist for highly or moderately emetogenic chemotherapy • Anzemet injection solution prolongs the QT interval in a dose dependent fashion. Torsades de Pointes has been reported during post-marketing experience. Avoid Anzemet in patients with congenital long QT syndrome, hypokalemia or hypomagnesemia. • Anzemet injection solution administered intravenously is contraindicated in adult and pediatric patients for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy due to dose dependent QT prolongation. • When prophylaxis has failed using Anezemt injection, a repeat dose should not be initiated as rescue therapy. • Serotonin subtype 3 (5-HT3) receptor antagonist may cause serotonin syndrome alone but particularly with concomitant use of serotonergic drugs. • According to the 2011 American Society of Clinical Oncology (ASCO) Guideline for Antiemetics in Oncology, the Update Committee recommends the following: • For chemotherapy of high emetic risk - three-drug combination of 5-hydroxytryptamine-3 (5-HT3) serotonin receptor antagonist, dexamethasone, and aprepitant. The oral combination of netupitant and palonosetron plus dexamethasone is an additional treatment option in this setting. For chemotherapy of moderate emetic risk - two-drug combination of a 5-HT3 serotonin receptor antagonist and dexamethasone • Per practice guidelines from the National Comprehensive Cancer Network (NCCN), selection of emetogenic agents used should be based on the emetic risk of the therapy, prior experience with antiemetics, as well as patient risk factors. • The following table is NCCN’s classification for emetogenic potential of significant chemotherapy and other agents. Draft Prepared: December 17, 2002 3 Approved by Health Net Pharmacy and Therapeutics Committee: 4.11.06, 5.16.07, 05.21.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 10.17.03, 1.24.05, 12.07.05 RJL, 01.02.06 JP, 02.06.06 RJL, 02.27.06 RJL, 08.18.06 RO, 04.03.07 RO, 9.20.07 RO, 1.04.08 RO, 08.08.08 RO, 08.01.09 R Olegario, 10.26.10 R Olegario, 06.07.11 A Giordano, 7.12.12 R. Gedey, 07.11.13 MJMcClusky,07.07.14 S Mirando, 06.19.15 T You02.10S Ahantab, 12.15.16 M Del Nero Prior Authorization Protocol ALOXI (palonosetron), ANZEMET (dolasetron), SANCUSO , GRANISOL ™ (granisetron) NATL Agents Frequency of Emesis AC combination defined as either doxorubicin or epirubicin with cyclophosphamide, carmustine > 250 mg/m 2, cisplatin, 2 High Emetic Risk cyclophosphamide > 1,500 mg/m , doxorubicin ≥ 60mg/m², epirubicin >90% >90mg/m², ifosfamide ≥ 2gm/m² per dose, dacarbazine, mechlorethamine, streptozocin aldesleukin > 12-15 million IU/m 2, amifostine > 300 mg/m 2, arsenic trioxide, azacitidine, bendamustine, busulfan, carboplatin, carmustine ≤ 250 mg/m 2, , clofarabine, cyclophosphamide ≤ 1500 mg/m 2, cytarabine Moderate Emetic Risk > 200mg/m 2, dactinomycin, daunorubicin, doxorubicin < 60 mg/m2, 30-90% epirubicin ≤ 90mg/m², idarubicin, ifosfamide < 2gm/m² per dose, interferon alpha ≥ 10 million IU/m 2, irinotecan, melphalan, MTX ≥ 250 mg/m 2, oxaliplatin, temozolomide ado-trastuzumab emtansine, amifostine ≤ 300 mg, aldesleukin ≤ 12 million IU/m 2, brentuximab vedotin,cabazitaxel, carfilzomib, cytarabine (low dose) 100 - 200 mg/m 2, docetaxel, doxorubicin (liposomal), eribulin,etoposide, 5-fluorouracil, floxuridine, gemcitabine, interferon Low Emetic Risk alpha > 5 <10 million IU/m 2, ixabepilone, MTX > 50 mg/m 2 < 250 10-30% mg/m 2, mitomcyin, mitoxantrone, omacetaxine,paclitaxel, paclitaxel- albumin, pemetrexed, pentostatin,pralatrexate, romidepsin, thiotepa, topotecan, ziv-aflibercept alemtuzumab, asparaginase, bevacizumab, bleomycin, bortezomib, cetuximab, 2-chlorodeoxyadenosine (cladribine), cytarabine < 100mg/m 2, decitabine, denileukin diftitox, dexrazoxane, fludarabine, , Minimal Emetic Risk interferon alpha ≤ 5 million IU/m 2, ipilimumab, MTX ≤ 50 mg/m 2, <10% nelarabine, ofatumumab, panitumumab, pegaspargase,peginterferon, pertuzumab, rituximab, temsirolimus, trastuzumab, valrubicin, vinblastine, vincristine, vincristine (liposomal), vinorelbine altretamine, busulfan ( ≥ 4 mg/d), crizotinib, cyclophosphamide ( ≥ 100 Emetogenic potential of mg/m 2/d), estramustine, etoposide, lomustine (single day), mitotane, oral antineoplastic procarbazine, temozolomide (> 75 mg/m 2/d), vismodegib agents: Moderate to High axitinib,bexarotene, bosutinib, busulfan (< 4 mg/d), cabozantinib, capecitabine, chlorambucil, cyclophosphamide (< 100 mg/m 2/d), dasatinib,dabrafenib, erlotinib, everolimus, fludarabine, gefitinib, Emetogenic potential of hydroxyurea, imatinib, lapatinib, lenalidomide, melphalan, oral antineoplastic mercaptopurine, methotrexate, nilotinib, pazopanib, pomalidomide, agents: Minimal to low ponatinib, regorafenib, ruxolitinib,sorafenib, sunitinib, temozolomide ( ≤ 75 mg/m 2/d), thalidomide, thioguanine, topotecan,trametinib, tretinoin, vandetanib, vemurafenib, vorinostat V. Therapeutic Alternatives: Draft Prepared: December 17, 2002 4 Approved by Health Net Pharmacy
Load more

Recommended publications
  • CP.PMN.158 Netupitant and Palonosetron (Akynzeo)
    Clinical Policy: Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) Reference Number: CP.PMN.158 Effective Date: 09.01.06 Last Review Date: 02.21 Coding Implications Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Netupitant/palonosetron (Akynzeo®) and fosnetupitant/palonosetron are fixed combination products of netupitant, a substance P/neurokinin 1 (NK1) receptor antagonist, and palonosetron hydrochloride, a serotonin (5-HT3) receptor antagonist. FDA Approved Indication(s) Akynzeo capsules are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Akynzeo is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Prevention of Nausea and Vomiting Associated with Cancer Chemotherapy (must meet all): 1. Prescribed for the prevention of chemotherapy-induced nausea/vomiting; 2. Age ≥ 18 years; 3. If request is for Akynzeo capsules, member is scheduled to receive moderately to highly emetogenic cancer chemotherapy (see Appendix D); 4. If request is for Akynzeo for injection, member is scheduled to receive highly emetogenic cancer chemotherapy (see Appendix D); 5.
    [Show full text]
  • Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA
    JK SCIENCE ORIGINAL ARTICLE Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA Vishal Gupta, Renu Wakhloo, Anjali Mehta, Satya Dev Gupta Abstract The aim of the present study was to compare the antiemetic effect of intravenous Granisetron, Ondansetron & Metoclopramide in a randomized blinded study for prophylaxis of post operative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy under general anaesthesia. 60 patients (ASA I & II) undergoing laparoscopic cholecystectomy under general anaesthesia were randomly allocated into three equal groups (n=20). Emetic episodes in first 24 hours were recorded and compared in different study groups. Results were analyzed. Minimal emetic episodes were observed in early post-operative period (1-12hrs) in patients who had received intravenous granisetron in comparison to ondansetron and metoclopramide. However, after 12 hours emesis free periods were statistically insignificant between group A and B while patients in group C had no antiemetic effect. Keywords Post Operative Nausea and Vomiting (PONV), Granisetron, Ondensetron, Metoclopramide Introduction The most common and distressing symptoms, which vascular anastomoses and increased intracranial follow anaesthesia and surgery, are pain and emesis. The pressure(4). The anaesthetic consequences are aspiration syndrome of nausea, retching and vomiting is known as pneumonitis and discomfort in recovery. For institutions 'sickness' and each part of it can be distinguished as a there is increased financial burden because of increased separate entity (1). PONV (post operative nausea and nursing care, delayed discharge from Phase I and II vomiting) has been characterized as big 'little problem(2) recovery units and unexpected admissions. Hence, and has been a common complication for both in patients prophylactic antiemetic therapy is needed for all these and out patients undergoing virtually all types of surgical patients.
    [Show full text]
  • KYTRIL (Granisetron Hydrochloride) Injection Is an Antinauseant and Antiemetic Agent
    KYTRIL® (granisetron hydrochloride) INJECTION Rx only DESCRIPTION KYTRIL (granisetron hydrochloride) Injection is an antinauseant and antiemetic agent. Chemically it is endo-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole- 3-carboxamide hydrochloride with a molecular weight of 348.9 (312.4 free base). Its empirical formula is C18H24N4O•HCl, while its chemical structure is: granisetron hydrochloride Granisetron hydrochloride is a white to off-white solid that is readily soluble in water and normal saline at 20°C. KYTRIL Injection is a clear, colorless, sterile, nonpyrogenic, aqueous solution for intravenous administration. KYTRIL 1 mg/1 mL is available in 1 mL single-use and 4 mL multi-use vials. KYTRIL 0.1 mg/1 mL is available in a 1 mL single-use vial. 1 mg/1 mL: Each 1 mL contains 1.12 mg granisetron hydrochloride equivalent to granisetron, 1 mg; sodium chloride, 9 mg; citric acid, 2 mg; and benzyl alcohol, 10 mg, as a preservative. The solution’s pH ranges from 4.0 to 6.0. 0.1 mg/1 mL: Each 1 mL contains 0.112 mg granisetron hydrochloride equivalent to granisetron, 0.1 mg; sodium chloride, 9 mg; citric acid, 2 mg. Contains no preservative. The solution’s pH ranges from 4.0 to 6.0. CLINICAL PHARMACOLOGY Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2- or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors.
    [Show full text]
  • A Comparative Study of Ondansetron and Granisetron in Combination With
    International Journal of Research in Medical Sciences Nanjundaswamy NH et al. Int J Res Med Sci. 2018 Feb;6(2):503-508 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180288 Original Research Article A comparative study of ondansetron and granisetron in combination with dexamethasone-in prophylaxis for postoperative nausea and vomiting (PONV) in laproscopic cholecystectomies Nethra H. Nanjundaswamy, Raghavendra Biligiri Sridhara* Department of Anaesthesiology, Bangalore Medical College and Research Institute, Banglaore, Karnataka, India Received: 10 January 2018 Accepted: 15 January 2018 *Correspondence: Dr. Raghavendra Biligiri Sridhara, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Post operative nausea and vomiting (PONV) is a common problem and distressing symptom in surgical patient population. General anaesthesia with inhalational agents is associated with an average PONV incidence of 20- 30 % in surgical patients. PONV is difficult to treat and needs multiple drugs and combination of drugs. Granisetron and Ondansetron are among the commonly used 5HT3 antagonists and used in combination with dexamethasone for prophylaxis against PONV. The aim of the study was to compare the efficacy of combination of antiemetics- Ondansetron 4mg+Dexamethasone 8mg and Granisetron 1mg+Dexamethasone 8mg in prevention of post operative nausea and vomiting. Methods: 75 patients of ASA 1 and 2 were randomly allocated to three groups-Group 1 (n=25) received Ondansetron 4mg+Dexamethasone 8mg; Group 2 (n=25)-received Granisetron 1mg+Dexamethasone 8mg; Group 3-received saline with dexamethasone 8mg.
    [Show full text]
  • Akynzeo™ (Netupitant and Palonosetron) Capsule/ Antiemetics
    Drug Monograph Drug/Drug Akynzeo™ (netupitant and palonosetron) capsule/ Class: Antiemetics Prepared for: MO HealthNet Prepared by: Xerox Heritage, LLC New Criteria Revision of Existing Criteria Executive Summary The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open Purpose: access basis to prescribers, require a clinical edit or require prior authorization for use. Akynzeo™ is available as a 300 mg/0.5 mg capsule containing 300 mg of netupitant and 0.5 mg of palonosetron respectively. Dosage Forms & Manufacturer: Eisai Inc, Woodcliff Lake, NJ The efficacy of Akynzeo™ for the prevention of acute and delayed nausea and vomiting due to chemotherapy was demonstrated in two phase 3 clinical trials. Complete response rates (ie, no emesis and no rescue medication) for acute, delayed, and overall nausea and vomiting following a single cycle of moderately emetogenic chemotherapy (n=1455) were 88.4%, 76.9%, and 74.3% for Akynzeo™ plus dexamethasone compared Summary of with 85%, 69.5%, and 66.6% for palonosetron plus dexamethasone. In a Findings: second phase 3 study where patients were randomized to receive Akynzeo™ or aprepitant plus palonosetron (with all patients receiving dexamethasone) for repeated cycles of highly or moderately emetogenic chemotherapy (n=412), complete response rates for the overall phase of nausea and vomiting ranged from 81% to 92% for the Akynzeo™ arm and 76% to 88% for the aprepitant/palonosetron arm through 6 cycles of chemotherapy. Status Prior Authorization (PA) Required Open Access Recommendation: Clinical Edit PDL Type of PA Increased Risk of ADE Preferred Agent Criteria: Appropriate Indications Under Solicitation 2015 Xerox Heritage, LLC All Rights Reserved.
    [Show full text]
  • Comparative Study of Palonosetron and Ondansetron in Prevention of Post Operative Nausea and Vomiting After Laparoscopic Gynaecological Surgeries
    Indian Journal of Clinical Anaesthesia 2020;7(1):59–63 Content available at: iponlinejournal.com Indian Journal of Clinical Anaesthesia Journal homepage: www.innovativepublication.com Original Research Article Comparative study of palonosetron and ondansetron in prevention of post operative nausea and vomiting after laparoscopic gynaecological surgeries Ankita Choudhary1,*, Vinod Parashar1 1Dept. of Anaesthesiology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India ARTICLEINFO ABSTRACT Article history: Introduction: Post operative nausea and vomiting (PONV) is a common complication after general Received 13-04-2019 anaesthesia, specially post laparoscopic surgeries. This study compared efficacy of palonosetron with Accepted 20-11-2019 ondansetron for prevention and management of PONV in patients undergoing laparoscopic gynaecological Available online 28-02-2020 surgeries. Materials and Methods : 100 patients, undergoing laparoscopic gynaecological surgery were randomly divided in 2 groups of 50 each. They received either ondansetron(4mg IV) or palonosetron (0.075mg IV) Keywords: before induction of general anaesthesia. They were monitored post operatively till 72 hours for episodes of Palonosetron nausea, vomiting, overall PONV and adverse effects. Post operative nausea vomiting Result: The incidence of overall PONV was significantly less in patients who received palonosetron as Laparoscopic gynaecological compared those who received ondansetron. Also, ondansetron group demonstrated higher use of rescue surgeries anti-emetic drug as compared with palonosetron group. No significant difference was found in incidence Anti-emetic drugs of adverse effects in both groups. Ondansetron Conclusion: Palonosetron, having longer duration of action, is more effective in treating long term PONV compared to ondansetron in patients undergoing laparoscopic gynaecological surgeries under general anesthesia. © 2020 Published by Innovative Publication.
    [Show full text]
  • Comparison of Granisetron Plus Dexamethasone Versus An
    Published online: 2021-07-19 ORIGINAL ARTICLE Comparison of granisetron plus dexamethasone versus an antiemetic cocktail containing midazolam and diphenhydramine for chemotherapy induced nausea and vomiting in children Suna Emir, Pınar Erturgut, ABSTRACT Sadi Vidinlisan1 Background: Chemotherapy induced nausea and vomiting (CINV) is one of the most Department of Pediatric disturbing side-effects in children receiving highly emetogenic chemotherapy. We Hematology Oncology and aimed to assess whether the addition of an antiemetic cocktail containing midazolam 1 Department of Pediatrics, SB and diphenhydramine to granisetron plus dexamethasone combination could ameliorate Ankara Children’s Hematology CINV in this study. Patients and Methods: A total of 23 children aged between 1 and Oncology Training and Research Hospital, Ankara, Turkey 16 years to receive cisplatin containing chemotherapy in our clinic were included in this study from April 2007 to April 2008. 76 cycles in 23 patients were randomly assigned to receive either antiemetic regimen 1 or antiemetic regimen 2. Antiemetic regimen 1 containing granisetron 0, 04 mg/kg plus dexamethasone 0, 2 mg/kg were given in 45 chemotherapy cycles. In 31 cycles, an antiemetic cocktail containing midazolam 0, 04 mg/kg, diphenhyramine 2, 5 mg/ kg in addition to granisetron plus dexamethasone was given. Number of vomiting, severity of nausea, the use of rescue therapy and adverse events were assessed between day 1 and day 5. Results: Complete response for the acute phase was observed 38/45 (84, 4%) cycles in regimen 1 as compared with 28/31 (90, 3%) in regimen 2, antiemetic cocktail regimen (P > 0.05). Complete response for delayed emesis after 24 h of the beginning of chemotherapy was observed in 29/45 (64, 4 %) in regimen 1 and 16/31 (51, 6%) in regimen 2.
    [Show full text]
  • Prophylaxis with Oral Granisetron for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy a Prospective Randomized Study
    ORIGINAL ARTICLE Prophylaxis With Oral Granisetron for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy A Prospective Randomized Study Yoshitaka Fujii, MD; Hiroyoshi Tanaka, MD; Tsuneo Kawasaki, MD Hypothesis: Laparoscopic cholecystectomy is associ- dard general anesthetic technique and postoperative ated with a relatively high incidence of postoperative nau- analgesia were used. sea and vomiting when no prophylactic antiemetic is given. This study assesses the efficacy and safety of oral Main Outcome Measures: Emetic episodes were re- granisetron hydrochloride for the prevention of nausea corded during the first 24 hours after anesthesia. and vomiting after laparoscopic cholecystectomy. Results: The incidence of patients who were emesis- Design: A prospective, randomized, double-blind, pla- free 24 hours after anesthesia was 60% with 1 mg of granise- cebo-controlled study. tron (P=.40), 83% with 2 mg of granisetron (P=.01), and 83% with 4 mg of granisetron (P=.01), compared with Setting: University teaching hospital. placebo (53%). No clinically important adverse effects were observed in any of the groups. Patients: The study comprised 120 patients, 92 women and 28 men, undergoing laparoscopic cholecystectomy. Conclusion: Preoperative oral granisetron in doses higher than 2 mg is effective for the prevention of nausea and Interventions: Patients received orally either placebo vomiting after laparoscopic cholecystectomy. or granisetron at 3 different doses (1 mg, 2 mg, and 4 mg; n=30 of each) 60 minutes before
    [Show full text]
  • Economic Analysis of Palonosetron Versus
    Shimizu et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:31 https://doi.org/10.1186/s40780-018-0128-9 RESEARCHARTICLE Open Access Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial) Hisanori Shimizu1,13* , Kenichi Suzuki2, Takeshi Uchikura1, Daiki Tsuji3, Takeharu Yamanaka4, Hironobu Hashimoto5, Koichi Goto6, Reiko Matsui7, Nobuhiko Seki8, Toshikazu Shimada9, Shunya Ikeda10, Naoki Ikegami11, Toshihiro Hama2, Nobuyuki Yamamoto12 and Tadanori Sasaki1 Abstract Background: We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC). Methods: We retrospectively investigated all medicines prescribed for antiemetic purposes within 120 h after the initiation of cisplatin administration during hospitalization. In the TRIPLE study, patients were assigned to treatment with granisetron (GRA) 1 mg (n = 413) or palonosetron (PALO) 0.75 mg (n = 414). The evaluation measure was the cost-effectiveness ratio (CER) assessed as the cost per complete response (CR; no vomiting/ retching and no rescue medication). The analysis was conducted from the public healthcare payer’s perspective. Results: The CR rates were 59.1% in the GRA group and 65.7% in the PALO group (P = 0.0539), and the total frequencies of rescue medication use for these groups were 717 (153/413 patients) and 573 (123/414 patients), respectively.
    [Show full text]
  • Medication Coverage Policy
    MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 12/14/2016 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 11/07, 11/15 LOB AFFECTED Medi-Cal, SJHA (MONTH/YEAR) OVERVIEW Prescription and OTC antiemetic medications are used to relieve nausea and/or prevent or stop vomiting. Some medications have more evidence of providing benefit in specific patient populations, such as patients taking chemotherapy or undergoing a procedure that requires anesthesia. While there are many available agents to relieve the symptoms of nausea and vomiting, non-pharmacologic recommendations should be incorporated into every patient care plan.1,2,3 The purpose of this coverage policy is to review the coverage criteria of HPSJ’s formulary anti-nausea agents (Table 1). Table 1: Available Anti-Nausea Medications Generic (Brand) Strength & Dosage form Formulary Notes Limits 5-HT3 Antagonists Dolasetron Anzemet 50 mg tablet PA; SP Reserved for treatment failure of (Anzemet) Anzemet 100 mg tablet PA; SP Ondansetron and Granisetron Tablets Reserved for members with documented Granisetron 3.1 mg/24 hr PA; SP inability to take medications by mouth, transdermal patch (Sancuso Granisetron (Kytril, including ODT formulations. Sancuso) Reserved for patients with documented Granisetron Tablets (Kytril) PA treatment failure of dose optimized Ondansetron therapy Ondansetron 4 mg disintegrating QL tablet Ondansetron 8 mg disintegrating QL Limit 60 tablets per 30 days. tablet Ondansetron Ondansetron Hcl 4 mg tablet QL (Zofran) Ondansetron Hcl 8 mg tablet QL Ondansetron 4 mg/5 ml solution NF Ondansetron 40 mg/20 ml vial NF Ondansetron HCL 4 mg/2 ml vial NF Reserved for use in patients receiving Palonosetron Aloxi 0.25 mg/5 ml intravenous highly-emetogenic chemotherapy, with PA; SP (Aloxi) solution treatment failure of ondansetron, or documented inability to swallow.
    [Show full text]
  • Granisetron: Pediatric Medication
    PATIENT & CAREGIVER EDUCATION Granisetron This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Sancuso; Sustol Brand Names: Canada APO-Granisetron; JAMP Granisetron; NAT-Granisetron What is this drug used for? It is used to prevent upset stomach and throwing up. Long-acting injection and skin patch: If your child has been given this form of this drug, talk with the doctor for information about the benefits and risks. Talk with the doctor if you have questions or concerns about giving this drug to your child. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child is using another drug that has the same drug in it. If your child is taking apomorphine. Granisetron 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell the doctor and pharmacist about all of your child’s drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe to give this drug with all of your child’s other drugs and health problems. Do not start, stop, or change the dose of any drug your child takes without checking with the doctor.
    [Show full text]
  • ALOXI, INN-Palonosetron
    SCIENTIFIC DISCUSSION 1. Introduction Aloxi contains palonosetron, a 5-hydroxytryptamine (serotonin) type 3 receptor antagonist, as active substance. With the present application, the applicant sought a marketing authorisation in the following indication: - “the prevention of acute nausea and vomiting associated with initial and repeat course of moderately and highly emetogenic cancer chemotherapy and - the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.” Chemotherapy-induced nausea and vomiting (CINV) CINV can be broadly categorised as acute, when nausea and vomiting occur within 24 hours after the start of chemotherapy [1], delayed, if CINV persist for 6 to 7 days after therapy [2, 3], or anticipatory, if CINV occur prior to chemotherapy administration [2, 4]. Chemotherapy agents have a highly variable emetogenic potential and can be classified according to their emetogenic level as agents with low, intermediate and high emetogenic risk. CINV remains a significant side effect experienced by cancer patients especially when treated with highly emetogenic regimens. It can impair patient’s quality of life and in case it becomes serious, dehydration, malnutrition, metabolic disturbances, and aspiration pneumonia may occur. As a consequence, control of nausea and vomiting plays an important part in the overall treatment success for cancer patients. The precise mechanisms by which chemotherapy induces nausea and vomiting are unknown. However, it appears probable that different chemotherapeutic agents act at different sites and that some chemotherapeutic agents act at multiple sites [5]. The mechanisms by which chemotherapeutic agents cause nausea and vomiting are activation of the chemoreceptor trigger zone (CTZ) either directly or indirectly, peripheral stimulation of the gastrointestinal tract, vestibular mechanisms, cortical mechanisms, or alterations of taste and smell [6].
    [Show full text]